Relationship between Outer Membrane Protein Profiles and Resistance to Ceftazidime, Imipenem, and Ciprofloxacin in Pseudomonas aeruginosa Isolates from Bacteremic Patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 1, 1996, Pages 82-85

  Gimeno, C ^a   Navarro, D ^a   Savall, F ^a   Millas E ^a   Farga, M A ^a   Garau, J ^b   Cisterna, R ^c   Garcia De Lomas J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b H Mutua de Tarrassa   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; OUTER MEMBRANE PROTEIN; THIENAMYCIN DERIVATIVE;

ARTICLE; BACTEREMIA; CHEMISTRY; DRUG EFFECT; HUMAN; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; CEFTAZIDIME; CEPHALOSPORINS; CIPROFLOXACIN; HUMANS; IMIPENEM; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 0029687102     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01586192     Document Type: Article

References (22)

1. Sanders CC, Sanders WE: β-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clinical Infectious Diseases 1992, 15: 824-839.
2. Büscher K-H, Cullmann W, Dick W, Opferkuch W: Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrobial Agents and Chemotherapy 1987, 31: 703-708.
3. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA: Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. Journal of Infectious Diseases 1986, 154: 289-294.
4. Margaret BS, Drusano GL, Standiford HC: Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 161-168.
5. Vurma-Rapp U, Kayser F-H, Hadorn K, Wiederhehr F: Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy. European Journal of Clinical Microbiology & Infectious Diseases 1990, 9: 580-587.
6. Piddock LJV, Turner HL: Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae. European Journal of Clinical Microbiology & Infectious Diseases 1992, 11: 1187-1191.
7. Trias J, Nikaido H: Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1990, 34: 52-57.
8. Satake S, Yoneyama H, Nakae T: Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1990, 28: 199-207.
9. Livermore DM: Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1992, 36: 2046-2048.
10. Zhou XY, Kitzis MD, Gutmann L: Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1993, 37: 1387-1389.
11. Lewin CS, Allen RA, Amyes SGB: Potential mechanism of resistance to modern fluorinated-quinolones. Journal of Medical Microbiology 1990, 31: 153-161.
12. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. NCCLS, Villanova, PA, 1993.
13. Bradford M: A rapid sensitive method for the quantitation of microgram quantities of protein-dye binding. Analytical Biochemistry 1976, 72: 248-254.
14. Plykaytis BD, Carlone GM, Edmonds P, Mayer LW: Robust estimation of standard curves for protein molecular weight and linear-duplex DNA pair base numbers after gel electrophoresis. Analytical Biochemistry 1986, 152: 346-364.
15. Sanders WE, Sanders CC: Inducible β-lactamases of gram-negative bacteria and their possible physiological role. Reviews of Infectious Diseases 1988, 10: 830-838.
16. Bush K: Characterization of β-lactamases. Antimicrobial Agents and Chemotherapy 1989, 33: 259-263.
17. Garau J: β-lactamases: current situation and clinical importance. Intensive Care Medicine 1994, 20: 55-59.
18. Philipon A, Labia R, Jacoby GA: Extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1989, 33: 1131-1136.
19. Satake S, Yoshihara E, Nakae T: Diffusion of β-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1990, 34: 685-690.
20. Yoshida H, Nakamura M, Bogaki M, Nakamura S: Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1990, 34: 1273-1275.
21. Yoshida T, Muratani T, Iyobe S, Mitsuhashi S: Mechanisms of high level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1994, 38: 1466-1469.
22. Huang H, Hancock REW: Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. Journal of Bacteriology 1993, 175: 7793-7800.